PHM-Exch> India: Novartis & access to medicines (2)

[Claudio Schuftan]

   From:    slim.slama at hcuge.ch


It is interesting to note that Novartis is currently massively investing in
China, putting itd R&D investment in India on hold.

See the following article with related references in a Canadian biotech
blog:

http://crossborderbiotech.ca/2009/11/12/trends-update-ip-constituencies-novartis-ceo-vasella-calls-upcoming-gleevec-decision-a-turning-point-for-rd-in-india/

As to the Glivec case, Novartis has posted the following responses on its
website:

History of Glivec in India:
http://www.novartis.com/downloads/about-novartis/glivec-history-india.pdf

and Glivec Patent Case in India: FACT vs. FICTION:

http://www.novartis.com/downloads/about-novartis/facts-vs-fiction-india-glivec-patent-case.pdf

SpicyIP blog has several interesting posts on the IPR politics in India, the
case of Glivec is discussed here:

http://spicyipindia.blogspot.com/2007/09/novartis-patent-saga-flawed-strategy.html

see also:
http://spicyipindia.blogspot.com/2009/07/breaking-news-novartis-loses-glivec.html
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://phm.phmovement.org/pipermail/phm-exchange-phmovement.org/attachments/20091230/f724de36/attachment-0001.html>